{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-25-000077","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2025-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.562501+00:00","generated_at":"2026-05-16T13:22:50.166370+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LENZ Therapeutics addresses FAERS report of retinal tear in VIZZ patient with pre-existing risk factors","bullets":["FAERS report describes retinal tear in a patient using VIZZ (aceclidine ophthalmic solution) 1.44%.","Patient had significant retinal pathology history: lattice degeneration, prior laser, previous tear; no recent peripheral exam.","Independent retina specialists note multiple pre-existing risk factors making spontaneous retinal events more likely.","Company states this initial report does not alter current safety expectations for VIZZ."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-25-000077","json":"https://secwatch.observer/filing/0001815776-25-000077.json","markdown":"https://secwatch.observer/filing/0001815776-25-000077.md","text":"https://secwatch.observer/filing/0001815776-25-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000077/0001815776-25-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000077/lenz-20251212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:22:50.166370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}